First Financial Bank Trust Division Sells 37,937 Shares of Johnson & Johnson (NYSE:JNJ)

First Financial Bank Trust Division lessened its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 63.0% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 22,288 shares of the company’s stock after selling 37,937 shares during the quarter. First Financial Bank Trust Division’s holdings in Johnson & Johnson were worth $3,696,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. WealthTrak Capital Management LLC bought a new position in Johnson & Johnson during the fourth quarter worth about $26,000. Mountain Hill Investment Partners Corp. bought a new position in Johnson & Johnson during the fourth quarter worth about $29,000. Bay Harbor Wealth Management LLC bought a new position in Johnson & Johnson during the fourth quarter worth about $32,000. Conquis Financial LLC bought a new position in Johnson & Johnson during the fourth quarter worth about $33,000. Finally, Bernard Wealth Management Corp. bought a new position in Johnson & Johnson during the fourth quarter worth about $36,000. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Stock Down 0.5%

Shares of NYSE JNJ opened at $152.53 on Thursday. Johnson & Johnson has a one year low of $140.68 and a one year high of $169.99. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86. The firm’s 50 day simple moving average is $154.63 and its two-hundred day simple moving average is $153.64. The stock has a market capitalization of $367.00 billion, a P/E ratio of 22.94, a PEG ratio of 2.56 and a beta of 0.42.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, beating analysts’ consensus estimates of $2.59 by $0.18. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The business had revenue of $21.89 billion for the quarter, compared to analysts’ expectations of $21.65 billion. As a group, analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th will be issued a $1.30 dividend. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.24. The ex-dividend date is Tuesday, May 27th. This represents a $5.20 annualized dividend and a dividend yield of 3.41%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 57.84%.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on JNJ. Royal Bank of Canada reissued an “outperform” rating and issued a $181.00 price target on shares of Johnson & Johnson in a report on Wednesday, April 16th. Bank of America lowered their price target on shares of Johnson & Johnson from $171.00 to $159.00 and set a “neutral” rating on the stock in a report on Thursday, April 10th. The Goldman Sachs Group raised shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and increased their price target for the stock from $157.00 to $172.00 in a report on Wednesday, April 9th. Leerink Partners downgraded shares of Johnson & Johnson from an “outperform” rating to a “market perform” rating and lowered their price target for the stock from $169.00 to $153.00 in a report on Tuesday, May 13th. Finally, Sanford C. Bernstein reissued a “market perform” rating on shares of Johnson & Johnson in a report on Wednesday, April 16th. Eleven research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $170.88.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.